Rachel Kelly is an instructor of medicine and associate epidemiologist at the Harvard Medical and Brigham and Women’s Hospital. Over the past 10 years, her primary focus has been on metabolomic epidemiology as a means to better understand common complex phenotypes and heterogeneous diseases. In particular, she is interested in neurological development and autism spectrum disorder (ASD). As part of this effort, Kelly is interested in applying novel statistical techniques, network approaches and integrative metabolomics to cohort and biobank data in order to improve our understanding of neurological development and associated disorders, and in particular to identify mechanistically informative ASD metabo-endotypes. Kelly is leading a number of initiatives focused on the metabolomics of ASD, including through the NIH-sponsored Environmental Influences on Child Health Outcomes (ECHO) program.